Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age

Table 2

Comparison of demographic data between patients treated with ranibizumab or bevacizumab.

	Ranibizumab ()		Bevacizumab ()
	Mean ± SD	Median (95% CI)	Mean ± SD	Median (95% CI)
GA (weeks)	26.54 ± 2.28	26.00 (25.00 to 27.45)	27.06 ± 2.43	27.00 (26.00 to 28.0)	0.38
BW (g)	856.15 ± 306.46	758.00 (642.36 to 1034.87)	911.08 ± 175.17	922.00 (810.31 to 1009.82)	0.23
PMA at IVI (weeks)	36.12 ± 2.72	36.00 (34.55 to 38.45)	37.19 ± 3.28	36.00 (35.00 to 38.00)	0.26
Corrected age (months)	34.77 ± 2.83	35.00 (33.65 to 36.45)	35.08 ± 1.97	35.00 (34.00 to 36.00)	0.80

BW: birth weight; GA: gestational age; PMA: postmenstrual age; Mann–Whitney U test.